

## DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L., 2009, *Drug Information Handbook, 17<sup>th</sup> edition*, Lexi-Comp for the American Pharmacist Association.
- Agustin, O. dan Fitrianiingsih, 2020, *Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan di Apotek X Jambi*, Universitas Jambi.
- Agutini, T., Arifin, H., Hanif, A., 2016, *Perbandingan Dosis Warfarin terhadap Durasi Tercapainya Target INR pada Pasien CHF dengan Atrial Fibrillation*, Jurnal Sains Farmasi dan Klinis, Ikatan Apoteker Indonesia, Sumatera Barat.
- American Heart Association (AHA), American College of Cardiology (ACC). 2006. *Warfarin Dosing Guideline*. Department of Surgical Education, Orlando Regional Medical Center. USA.
- Armaganijan, L., Patel, D., Dietrich, C., and Morillo, C.A., 2012, *Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines, Pharmaceutical*, p.386-387.
- Baker, R.I., Coughlin, P.B., Salem, H.H., Gallus, A.S., Harper, P.L., Wood, E.M., 2004, *Warfarin Reversal: Consensus Guidelines, on Behalf of the Australasian Society of Thrombosis and Haemostasis*. Medical Journal of Australia, 181(9): 492–497.
- BPOM RI, 2015, *Natrium warfarin*, Pusat Inforasi Obat Nasional, diakses online melalui <http://pionas.pom.go.id/monografi/natrium-warfarin> pada 27 Desember 2020 pukul 19.47 WIB.
- BPOM RI, 2016, *Antikoagulan Oral*, Pusat Informasi Obat Nasional, dapat diakses online melalui <http://pionas.pom.go.id/ioni/bab-2-sistem-kardiovaskuler-0/26-antikoagulan-dan-protamin/261-antikoagulan-oral> pada 3 Desember 2020 pukul 19.16 WIB.
- David, N., Juurlink, M.D., 2007, *Drug Interactions with Warfarin: What Clinicians Need to Know*, Canadian Medical Association.
- Departement of Health. 2016. *Guidelines for Warfarin Management in the Community. Queensland Health and the Royal Flying Doctor Service Queensland Section*. State of Queensland.
- Devi, G.A., Aryabiantara, I.W., Hartawan, 2018, *Profil Penggunaan Antikoagulan pada Pasien Kardiovaskular yang Dirawat di Ruang ICCU RSUP Sanglah*

*Periode Januari 2016-Juni 2016*, E-Jurnal Medika Vol 7, Universitas Udayana, Bali.

Dipiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B., Posey, L., 2011, *Pharmacotherapy: a Pathophysiologic Approach*, 8<sup>th</sup> edition, The McGraw-Hill Companies Inc, United States.

Eikelboom, J. W., dan Connolly, S. J., 2012, *Warfarin in Heart Failure*. *New England Journal of Medicine*, 366(20), 1936–1938. doi:10.1056/nejme1202504.

Haemost, J.T., 2014, *Thrombosis: a Major Contributor to the Global Disease Burden*, ISTH steering committee for world thrombosis day, 12: 1580–90.

Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M., 2015, *Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation*. *J Am Heart Assoc*;4(1):1–12.

Handajati, A., Roosihermatie, B., Maryani, H., 2009, *Faktor yang Berhubungan dengan Pola Kematian pada Penyakit Degeneratif di Indonesia*, Pusat Penelitian dan Pengembangan Sistem dan Kebijakan Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Surabaya.

Holbrook, A.M., 2005, *Systematic Overview of Warfarin and Its Drug and Food Interaction*. *Archives of Internal Medicine*, 165(10), 1095.

Holland, L., Warkentin, T.E., Refaai, M., Crowther, R., 2009, *Suboptimal Effect of a Three-Factor Prothrombin Complex Concentrate (Profilnine-SD) in Correcting Supratherapeutic International Normalized Ratio due to Warfarin Overdose*, *Transfusion Practice*, 49(6): 1171-1177.

Kemenkes, 2018, *Potret Sehat Indonesia dari Riskesdas 2018*, diperoleh dari [http://www.depkes.go.id/article/view/18110200003/potret-sehat-indonesia - dari-riskesdas-2018.html](http://www.depkes.go.id/article/view/18110200003/potret-sehat-indonesia-dari-riskesdas-2018.html), diakses pada 9 Juli 2021 pukul 19.47 WIB

Kemenkes, 2019, *Hipertensi Penyakit Paling Diidap Masyarakat*, Biro Komunikasi dan Pelayanan Masyarakat, Kementerian Kesehatan Republik Indonesia, diakses melalui [Kementerian Kesehatan Republik Indonesia \(kemkes.go.id\)](http://kemkes.go.id), pada 9 Juli 2021 pukul 20.09 WIB.

Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel N, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or

with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2021;77:629–58.

Lemeshow, S., Hosmer Jr., D.W., Klar, J., Lwanga, S.K., 1990, *Adequacy of Sample Size in Health Studies*, New York: World Health Organization.

Malhotra, K., Ishfaq, M. F., Goyal, N., Katsanos, A. H., Parissis, J., Alexandrov, A. W., ... Tsivgoulis, G., 2019, *Oral anticoagulation in patients with chronic kidney disease*. *Neurology*, 10.1212/WNL.0000000000007534. doi:10.1212/wnl.0000000000007534

Mazurek, M., Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H.-C., ... Lip, G. Y. H., 2018, *Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program*. *The American Journal of Medicine*, 131(8), 945–955.e3.

Megawati, S., Lestari, T., Setyani, W.L., 2019, *Evaluation of the Use Warfarin Oral on the INR Value of the Pathway Patients RSU of Kabupaten Tangerang in 2018*, STF Muhammadiyah Tangerang.

Morgan, C. L., McEwan, P., Tukiendorf, A., Robinson, P. A., Clemens, A., & Plumb, J. M., 2009, *Warfarin treatment in patients with atrial fibrillation : Observing outcomes associated with varying levels of INR control*. *Thrombosis Research*, 124, 37-41.

Nugraha, G., 2015, *Panduan Pemeriksaan Laboratorium Hematologi Dasar*: Trans Info Media, Jakarta Timur.

Nursamsu, A. dan Setiabudi, E., 2012, *The Efficacy of Novel Anticoagulants Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation*, Artikel Pengembangan Pendidikan Keprofesian Berkelanjutan, *J Indon Med Assuoe*, 61 (10).

Pagano, M. B., Chandler, W. L. dan Sam, C. M. E., 2012, *Bleeding Risks and Response to Therapy in Patients With INR Higher Than 9*. *Am J Pathol*, 138: 546–550.

Poller, L., 2004, *International Normalized Ratios (INR): the first 20 years*. *Journal of Thrombosis and Haemostasis*, 2(6): 849–860.

Pubchem, 2021, *Warfarin*, dapat diakses online melalui [Warfarin | C19H16O4 - PubChem \(nih.gov\)](https://pubchem.ncbi.nlm.nih.gov/compound/Warfarin) pada 17 Maret 2021 pukul 13.48 WIB.

Rambe, A., 2005, *Obat-Obat Penyakit Serebro Askular*, Neurologi Fakultas Kedokteran USU RSUP H. Adam Malik, USU digital library, Sumatera Utara.

- Sara, N.R., 2017, *Profil Nilai International Normalized Ratio (INR) pada Pasien Stroke Iskemik di Rumah Sakit Umum Daerah dr. Zainoel Abidin Banda Aceh*, Fakultas Kedokteran Universitas Syiah Kuala Darussalam Banda Aceh.
- Sasmita, E., 2017, *Hubungan Karakteristik Personal Pasien dengan Lama Rawat Pasien Moderate Care di Rumah Sakit Ortopedi Prof. Dr. R. Soeharso Surakarta*, Universitas Muhammadiyah Surakarta.
- Shikdar, S., Vashisht, r., Bhattacharya, P., 2021, *International Normalized Ratio (INR)*, Mercy Chatolic Medical Center, University of Phennsylvania, StatPearls Publishing LLC.
- Sonuga, B.O., Hellenberg, D.A., Cupido, C.S., Jaegar, C., 2016, *Profil and Anticoagualtion Outcome of Patients on Warfarin Therapyin an Urban Hospital in Cape Town, South Africa*, African Journal of Primary Health Care and Family Medicine.
- Sun, S., Wang, M., Su, L., Li, J., Li, H., Gu, D., 2006, *Study on Warfarin Plasma Concentration and Its Correlation with International Normalized Ratio*, Journal of Pharmaceutical and Biomedical Analysis, 42(2): 218–222
- Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Messé SR, Perino AC, Rodriguez F, Sarode R, Siegal DM, Wiggins BS, 2020, *ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee*. J Am Coll Cardiol 2020;76:594-622.
- Xue, L., Zhang, Y., Xie, C., Zhou, L., Liu, L., Zhang, H., ... Miao, L., 2019, *Relationship Between Warfarin Dosage and International Normalized Ratio: a Dose–Response Analysis and Evaluation Based On Multicenter Data*. *European Journal of Clinical Pharmacology*. doi:10.1007/s00228-019-02655-8
- Yulita, 2015, *Karakteristik Pasien Fibrilasi Atrium yang Dirawat Inap di Rumah Sakit Umum Pusat Haji Adam Malik*, Fakultas Kedokteran Universitas Sumatra Utara.
- Yuniadi Y, Tondas AE, Hanafy DA, Hermanto DY, Maharani E, Munawar M, et al., 2014, *Pedoman Tata Laksana Fibrilasi Atrium*. Edisi ke-1. Jakarta: Centra Communications; p. 1-73.